Preparation and characterization of an immunogenic meningococcal group A conjugate vaccine for use in Africa

Vaccine

Volumn 27, Issue 5, 2009, Pages 726-732

  Lee, Che Hung ^a   Kuo, Wen Chun ^a   Beri, Suresh ^b   Kapre, Subash ^b   Joshi, Jayant S ^b   Bouveret, Nancy ^c   LaForce, F Marc ^c   Frasch, Carl E ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^b India Ltd   (India)

^c Meningitis Vaccine Project   (France)

Author keywords

Conjugate; Polysaccharide; Vaccine

Indexed keywords

ALDEHYDE; ANTIBODY; HYDRAZIDE; MENINGOCOCCUS GROUP A POLYSACCHARIDE TETANUS TOXOID CONJUGATE VACCINE; MENINGOCOCCUS VACCINE; POLYSACCHARIDE; TETANUS TOXOID; UNCLASSIFIED DRUG;

AFRICA SOUTH OF THE SAHARA; AMINATION; ANIMAL EXPERIMENT; ANTIBODY BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; DRUG CONJUGATION; DRUG MECHANISM; DRUG SYNTHESIS; EPIDEMIC MENINGITIS; HUMAN; IMMUNOGENICITY; MOUSE; NEISSERIA MENINGITIDIS; NONHUMAN; PRIORITY JOURNAL;

ADULT; AFRICA; ANIMALS; ANTIBODIES, BACTERIAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNIZATION, SECONDARY; INDIA; INJECTIONS, SUBCUTANEOUS; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL VACCINES; MICE; MICROBIAL VIABILITY; NEISSERIA MENINGITIDIS, SEROGROUP A; TETANUS TOXOID; VACCINES, COMBINED; VACCINES, CONJUGATE;

EID: 58149496096     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.11.065     Document Type: Article

References (37)

1. World Health Organization. Emerging and other Communicable Diseases, surveillance and control, control of epidemic meningococcal diseases, WHO practical guidelines, 2nd ed. (1998)
2. Molesworth A.M., Thomson M.C., Connor S.J., Cresswell M.P., Morse A.P., Shears P., et al. Where is the meningitis belt? Defining an area at risk of epidemic meningitis in Africa. Trans R Soc Trop Med Hyg 96 (2002) 242-249
3. Greenwood B.M., Whittle H.C., Bradley A.K., Fayet M.T., and Gilles H.M. The duration of the antibody response to meningococcal vaccination in an African village. Trans R Soc Trop Med Hyg 74 (1980) 756-760
4. Robbins J.B., Towne D.W., Gotschlich E.C., and Schneerson R. Love's labours lost": failure to implement mass vaccination against group A meningococcal meningitis in sub-Saharan Africa. Lancet 350 (1997) 880-882
5. Robbins J.B., Schneerson R., and Gotschlich E.C. A Rebuttal: epidemic and endemic meningococcal meningitis in sub-Saharan Africa can be prevented now by routine immunization with group A meningococcal capsular polysaccharide vaccine. Pediatr Infect Dis J 19 (2000) 945-953
6. Gardner P. Prevention of meningococcal disease. N Engl J Med 355 (2006) 1466-1473
7. Harrison L.H. Prospects for vaccine prevention of meningococcal infection. Clin Microbiol Rev 19 (2006) 142-164
8. Reingold A.L., Broome C.V., Hightower A.W., Ajello G.W., Bolan G.A., Adamsbaum C., et al. Age-specific differences in duration of clinical protection after vaccination with meningococcal polysaccharide A vaccine. Lancet 326 (1985) 114-118
9. Lepow M.L., Goldschneider I., Gold R., Randolph M., and Gotschlich E.C. Persistence of antibody following immunization of children with group A and C meningococcal polysaccharide vaccines. Pediatrics 60 (1977) 673-680
10. Grothaus M.C., Srivastava N., Smithson S.L., Kieber-Emmons T., Williams D.B., Carlone G.M., et al. Selection of an immunogenic peptide mimic of the capsular polysaccharide of Neisseria meningitidis serogroup A using a peptide display library. Vaccine 18 (2000) 1253-1263
11. Schneerson R., Barrera O., Sutton A., and Robbins J.B. Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide protein conjugates. J Exp Med 152 (1980) 361-376
12. Lee CH, Frasch CE. Polysaccharide-protein conjugate vaccine. US Patent pending, US 2007/0141084 A1.
13. Silveira I.A.F.B., Bastos R.C., Neto M.S., Laranjeira A.P., Assis E.F., et al. Characterization and immunogenicity of meningococcal group C conjugate vaccine prepared using hydrazide-activated tetanus toxoid. Vaccine 25 (2007) 7261-7270
14. Comparison of Neisseria meningitidis serogroup W135 polysaccharide-tetanus toxoid conjugate vaccines made by periodate activation of O-acetylated, non-O-acetylated and chemically de-O-acetylated polysaccharide. Vaccine 25 (2007) 7972-7980
15. Lee C.H., and Frasch C.E. A method with increased yield for production of polysaccharide-protein conjugate vaccines using hydrazide chemistry. Proceedings of the 227th ACS National Meeting. Anaheim, CA, March 28-April 1 (2004), Americal Chemical Society, Division of Biochemical Technology [Abstract #82]
16. Frasch C.E., Kapre S., Beri S., Granoff D.M., Bouveret N., LaForce F.M., et al. A novel conjugation process for production of a highly immunogenic group A meningococcal conjugate vaccine for use in Africa. Proceedings of the 14th international pathogenic Neisseria conference. Milwaukee, Wisconsin, USA, September 5-10 (2004) 159 [Abstract]
17. LaForce F.M., Konde K., Viviani S., and Preziosi M.P. The Meningitis Vaccine Project. Vaccine 25S (2007) A97-A100
18. Jodar L., LaForce F.M., Ceccarini C., Aguado T., and Granoff D.M. Meningococcal conjugate vaccine for Africa: a model for development of new vaccine for the poorest countries. Lancet 361 (2003) 1092-1094
19. Ravenscroft N., Chen J., Hearshaw M., Mensah P., Beri S., Joshi J., et al. The application of physicochemical methods of analysis to the development of conjugate vaccines against meningococcal group A bacteria. Proceedings of the 15th international pathogenic Neisseria Conference. Cairns, Qld, Australia, September 10-15 (2006) [Abstract # P8.3.09]
20. Kshirsagar N., Mur N., Thatte U., Gogtay N., Viviani S., Preziosi M.P., et al. Safety, immunogenicity, and antibody persistence of a new meningococcal group A conjugate vaccine in healthy Indian adults. Vaccine 25S (2007) A101-A107
21. Sow S., Okoko B., Preziosi M.-P., Marchetti E., Tapia M., Adegbola R., et al. A phase 2, observer blind, randomized study to evaluate the safety and immunogenicity of a new meningococcal group A conjugate vaccine in healthy African toddlers residing in the Meningitis Belt. Poster in the conference of the 100th anniversary of the royal society of hygiene and tropical medicine. London, 12-13 September (2007)
22. BCA assay is according to the instruction provided by manufacturer (Pierce) of the assay kit
23. Lowry protein assay is according to the instruction provided by manufacturer (Pierce) of the assay kit
24. Vidal J. Trinitrophenyl-protein conjugates are more complex than it is currently thought. J Immunol Methods 86 (1986) 155-156
25. Keleti G., and Lederer W.H. Handbook of micromethods for the biological sciences. Phosphorus (total), vol. 70 (1974), Van Nostrand Reinhold Co., New York 84 pp
26. Maslanka S.E., Gheesling L.L., Libutti D.E., Donaldson K.B., Harakeh H.S., Dykes J.K., et al. Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group. Clin Diagn Lab Immunol 4 (1997) 156-167
27. Welsch J.A., and Granoff D.M. Immunity to Neisseria meningitidis group B in serum bactericidal-negative adults. Clin Vaccine Immunol 14 (2007) 1596-1602
28. Bundle D.R., Smith I.C.P., and Jennings H.J. Determination of the structure and conformation of bacterial polysaccharides by carbon 13 nuclear magnetic resonance. J Biol Chem 249 (1974) 2275-2281
29. 1H NMR assignment and detailed O-acetylation patterns of capsular polysaccharides from Neisseria meningitidis used in vaccine production. Carbohydr Res 296 (1996) 83-96
30. Wessels M.R., Paoletti L.C., Guttormsen H.K., Michon F., D'Ambra A.J., and Kasper D.L. Structural properties of group B Streptococcal type III polysaccharide conjugate vaccines that influence immunogenicity and efficacy. Infect Immunity 66 (1998) 2186-2192
31. Peeters C.C.A.M., Tenbergen-Meekes A.-M.J., Poolman J.T., Zegers B.J.M., and Rijkers G.T. Immunogenicity of a Streptococcus pneumoniae type 4 polysaccharide-protein conjugate vaccine is decreased by admixture of high dose of free saccharide. Vaccine 10 (1992) 833-840
32. Rodriguez M.E., Van der Dobbelsteen P.J.M., Oomen L.A., De Weers O., Van Buren L., Beurret M., et al. Immunogenicity of Streptococcus pneumoniae type 6B and 14 polysaccharide-tetanus toxoid conjugates and the effect of uncoupled polysaccharide on the antigen-specific immune response. Vaccine 16 (1998) 1941-1949
33. World Health Organization. Requirements for meningococcal polysaccharide vaccine. World Health Organ. Tech. Rep. Ser. 1976, 594:51-77.
34. Tiesjema R.H., Beuvery E.C., and Te Pas B.J. Enhanced stability of meningococcal polysaccharide vaccines by using lactose as a menstruum for lyophilization. Bull World Health Organ 55 (1977) 43-48
35. Jin Z., Chu C., Robbins J.B., and Schneerson R. Preparation and characterization of group A meningococcal capsular polysaccharide conjugates and evaluation of their immunogenicity in mice. Infect Immunity 71 (2003) 5115-5120
36. Inman J.K., and Dintzis H.M. The derivatization of cross-linked polyacrylamide beads. Controlled introduction of functional groups for the preparation of special-purpose, biochemical adsorbents. Biochemistry 8 (1969) 4074-4082
37. Berry D.S., Lynn F., Lee C.H., Frasch C.E., and Bash M.C. Effect of O-acetylation of Neisseria meningitidis serogroup A capsular polysaccharide on development of functional immune response. Infect Immunity 70 (2002) 3707-3713